CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
Business Wire•22/10/2026•07:05 ET
0
Key Highlights
- ➤AlloSure Kidney ≥1% linked to nearly 3-fold higher graft-loss or kidney-function decline risk
- ➤dd-cfDNA monitoring cut kidney transplant biopsies 49% versus surveillance biopsies
- ➤dd-cfDNA monitoring showed similar death, graft-loss, rejection, and 12-month kidney-function outcomes
- ➤AlloSure Kidney and AlloSure Plus maintained strong rejection prediction under Banff 2024 criteria
Expert Statements
Jeffrey Teuteberg, Chief Medical Officer of CareDx
“For decades, biopsy has been the reference standard for assessing rejection, despite being invasive; resulting in inconvenience, risk and stress for patients; and being resource-intensive for transplant programs.”
Jeffrey Teuteberg, Chief Medical Officer of CareDx
“These data show how AlloSure Kidney can provide clinically meaningful information across several of the most difficult decisions in kidney transplant care, from identifying risk when biopsy findings are ambiguous to enabling a less invasive approach to monitoring.”
Jeffrey Teuteberg, Chief Medical Officer of CareDx
“Combined with the long-term outcome data presented at this year’s ATC, the evidence increasingly supports the use of AlloSure Kidney to help clinicians assess risk and guide patient management.”
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
In an independent randomized trial, AlloSure-based monitoring demonstrates a significant reduction in kidney transplant biopsies while maintaining similar clinical outcomes
Get started
Create a free account to read the full story.